bullish thesi hum along nice price
remain overweight rate share follow decent print result
stronger anticip put take across board
includ humira imbruvica upsid big miss hcv franchis
post top- bottom-lin beat skyrizi strong launch continu new-to-
market rinvoq contribut sale inaugur print suspect
manag confirm process divest agn brazikumab
acquisit remain track close combin announc
dividend get double-digit increas continu like setup remain buyer
name
beat morn report top- bottom-lin beat non-
gaap ep consensu pjc total revenu
pjc driven decent perform immunolog
heme-onc portfolio includ humira beat vs consensu
pjc imbruvica beat vs consensu pjc
off-set hcv franchis miss vs consensu
pjc driven lower treat patient volum increas us competit
ep guidanc rais midpoint previous
consensu oper revenu growth guidanc rais
oper basi primarili driven increas guidanc ww
imbruvica sale approach vs previous ww skyrizi revenu
previous manag also announc dividend
increas note alreadi sport dividend yield
strong skyrizi launch continu nice inaugur print rinvoq ww skyrizi
revenu beat consensu pjc us sale q/q
vs initi ex-u sale inaugur print rinvoq revenu
essenti line consensu pjc
mayb littl ski skyrizi rinvoq estim quarter believ
survey work right derm rheum indic quick market penetr
continu recommend share allergan acquisit track close
divestitur brazikumab zenpep go two big launch
drive upsid like setup given today updat guidanc weve tweak
estim price target goe laps partial discount period
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit shaqe
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
